Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update

Disc Medicine posts strong cash, pivotal trial success, but commercialisation remains years away.

What the company is saying

Disc Medicine, Inc. (NASDAQ:IRON) is highlighting statistically significant topline results from its Phase 3 APOLLO trial for bitopertin in EPP, with CEO John Quisel, J.D., Ph.D., describing the data as 'strong and compelling evidence' and expressing intent to engage regulators for timely approval. The company emphasizes progress across its pipeline, including positive initial RESTORE-PV data for DISC-3405 in polycythemia vera and upcoming milestones for selcodebart (DISC-0974) in anemia of myelofibrosis and inflammatory bowel disease. The tone is confident, underlining a robust balance sheet following a $485.9 million public offering in October 2026 and a cash position of $682.8 million as of September 30, 2026. Disc asserts that these funds are sufficient to support operations and debt service into 2030. The company explains that lower R&D expenses and net loss versus the prior year are due to the absence of a $10.0 million milestone payment and non-recurring drug manufacturing costs, partially offset by higher personnel costs. The announcement foregrounds regulatory and clinical milestones, with commercialisation framed as an anticipated but not imminent event.

What the data suggests

The Phase 3 APOLLO trial for bitopertin achieved a 41.4% reduction in whole-blood metal-free PPIX versus placebo and increased average monthly total time in light without pain by 12.2 hours during month 6, both statistically significant. Dizziness occurred in 50% of bitopertin patients, all mild or moderate and transient, with no adverse events above Grade 3. Cash, cash equivalents, and marketable securities stood at $682.8 million at quarter-end, augmented by $485.9 million in net proceeds from an October 2026 public offering. Research and development expenses fell to $44.1 million in Q3 2026 from $50.3 million in Q3 2025, mainly due to a $10.0 million milestone payment and manufacturing costs in the prior period. SG&A expenses rose to $20.1 million from $17.4 million, attributed to increased headcount. Net loss narrowed to $59.5 million from $62.3 million, reflecting lower R&D spend. Claims regarding secondary and exploratory endpoints for bitopertin, and initial results for DISC-3405, are positive but lack quantitative detail. The company projects funding sufficiency into 2030, but no revenue or commercial launch is expected before mid-2027 at the earliest.

Analysis

The announcement is upbeat, highlighting statistically significant topline Phase 3 results for bitopertin and a strong cash position following a large public offering. The primary endpoint data for bitopertin is well-supported with specific numerical results, but claims regarding secondary and exploratory endpoints lack quantitative detail. Many forward-looking statements concern regulatory milestones (NDA resubmission, FDA decision) and future data presentations, with key commercial or clinical benefits not expected until at least mid-2027 or later. The company has raised substantial capital ($485.9M) and projects funding sufficiency into 2030, but there is no immediate path to revenue or profitability, and net losses continue. The tone is optimistic and at times promotional, especially regarding pipeline progress and anticipated launches, but the actual realised progress is limited to clinical trial data and improved financial runway, not commercialisation or earnings.

Risk flags

• ●Regulatory approval for bitopertin is not expected before mid-2027, so there is a significant execution gap between clinical trial success and commercial launch. Any delay or negative regulatory feedback could materially impact timelines and valuation.
• ●The company continues to operate at a net loss, with $59.5 million lost in Q3 2026. While current cash is sufficient to fund operations into 2030, sustained losses without revenue generation increase long-term dilution or financing risk if timelines slip.
• ●Claims of positive results for secondary and exploratory endpoints, as well as for DISC-3405 and selcodebart, are not supported by detailed numerical data or statistical values. This limits independent assessment of the robustness and commercial potential of these programs.
• ●The projected sufficiency of cash into 2030 assumes no major increases in burn rate, unexpected setbacks, or additional capital-intensive programs. Any adverse events, trial failures, or regulatory hurdles could accelerate cash usage and force earlier capital raises.
• ●The company is dependent on successful regulatory outcomes and timely execution of clinical milestones. Failure to deliver on these could erode investor confidence and delay or prevent commercialisation.

Bottom line

Disc Medicine has delivered statistically significant Phase 3 results for bitopertin in EPP and now holds $682.8 million in cash, bolstered by a $485.9 million public offering, providing a strong financial runway. The company's net loss narrowed to $59.5 million in Q3 2026, driven by lower R&D expenses after a $10.0 million milestone payment and manufacturing costs did not recur. While the topline clinical data for bitopertin is robust, claims for secondary endpoints and other pipeline assets lack quantitative detail, making it difficult to fully assess their commercial prospects. Regulatory approval for bitopertin is not expected before mid-2027, and other programs are even further from market, so near-term revenue is unlikely. The company is well-capitalised to pursue its pipeline, but the path to value realisation is long and subject to regulatory and execution risks. Investors should focus on upcoming regulatory milestones and look for more granular clinical data to better gauge the true potential of Disc's pipeline.

Announcement summary

(NASDAQ:IRON) Disc Medicine, Inc. reported financial results for the third quarter ended September 30, 2026, and provided updates on its clinical programs. The company announced positive topline data from the Phase 3 APOLLO clinical trial of bitopertin in EPP, achieving statistical significance on both co-primary endpoints: a 41.4% reduction in whole-blood metal-free PPIX versus placebo (p<0.0001) and a 12.2-hour increase in average monthly total time in light without pain during month 6 (p=0.0010). All secondary endpoints, including reductions in phototoxic reactions and improvements in light tolerance, were positive and statistically significant. Exploratory quality-of-life endpoints were also positive and statistically significant. Bitopertin was generally well-tolerated, with dizziness reported as the most common treatment emergent adverse event (TEAE) in 50% of the bitopertin group, all mild or moderate and transient, and no TEAEs above Grade 3. Disc plans to resubmit a New Drug Application (NDA) to the U.S. FDA by the end of 2026, with a decision anticipated by mid-2027. Updated data from the RALLY-MF trial of selcodebart (DISC-0974) will be presented at ASH in December, and feedback from an end of phase 2 FDA meeting and plans for pivotal development in anemia of MF will be announced by year-end. The Phase 2 study of selcodebart in inflammatory bowel disease (IBD) is progressing, with initial data expected in 2027. Positive initial results from the RESTORE-PV Phase 2 clinical trial of DISC-3405 in polycythemia vera (PV) were presented, showing increased hepcidin, lowered serum iron, controlled hematocrit, reduced phlebotomy, and improved symptoms; adverse events were consistent with underlying disease and injection site reactions were mild and self-limited. Updated RESTORE-PV data and initial efficacy data on the Q4 weekly dosed cohort, as well as initial data from a Phase 1b study of DISC-3405 in sickle cell disease, will be presented at ASH in December. As of September 30, 2026, cash, cash equivalents, and marketable securities totaled $682.8 million. In October 2026, Disc completed a public offering with net proceeds of approximately $485.9 million. The company believes these funds are sufficient to support current operating and capital expenditure plans and debt service obligations into 2030. Research and development expenses were $44.1 million for the three months ended September 30, 2026, compared to $50.3 million for the same period in 2025, with the decrease primarily due to a $10.0 million milestone payment and drug manufacturing costs in the prior period that did not recur. Selling, general and administrative expenses were $20.1 million for the three months ended September 30, 2026, compared to $17.4 million for the same period in 2025, primarily due to increased headcount. Net loss was $59.5 million for the three months ended September 30, 2026, compared to $62.3 million for the same period in 2025, with the decrease mainly due to lower R&D expenses.

Disagree with this article?